Ovarian Cancer
The clinical research activity is centered on ovarian cancer, with particular attention to recurrent disease and maintenance therapy in BRCA wild-type patients. The trial landscape reflects interest in treatment strategies aimed at prolonging disease control after initial response.
- Recurrent ovarian cancer
- Maintenance treatment
- BRCA wild-type disease
Research activity spans multiple collaborating sites across Europe, supporting clinical investigation in a cross-national gynecologic oncology setting.
Targeted Therapy and DNA Repair
The sponsor’s funded research includes interest in PARP inhibition through olaparib, with a focus on tumor control in the maintenance setting. This area reflects therapeutic attention to DNA damage response pathways in ovarian malignancy.
- Olaparib
- PARP inhibition
- DNA damage response
The research emphasis lies in therapies used to sustain remission and delay progression in women with epithelial ovarian cancer.
Immunotherapy
Another key area of interest is immune checkpoint inhibition, represented by durvalumab in combination-based maintenance strategies. The clinical focus includes integrating immuno-oncology approaches into care for gynecologic cancers.
- Durvalumab
- Immune checkpoint blockade
- Immuno-oncology
This therapeutic domain is directed toward improving disease management in patients with platinum-sensitive or recurrent ovarian cancer.
Cancer Vaccination
The trial portfolio also includes UV1, indicating interest in therapeutic cancer vaccination as part of combination maintenance treatment. This area aligns with research into antigen-directed immune activation in ovarian oncology.
- UV1
- Therapeutic cancer vaccine
- Immune activation
The sponsor’s research landscape includes combination strategies that link vaccination with targeted and immune-based therapies in ovarian cancer.
